Autogene cevumeran

Autogene cevumeran is an investigational mRNA vaccine being developed jointly by BioNTech and Genentech as an adjuvant therapy in cancer treatment to prevent cancer recurrence following surgery.[1][2][3]

Autogene cevumeran is a type of individualised neoantigen-specific immunotherapy containing multiple different mRNA species that together encode up to 20 neoantigens that have been identified in the resected tumour of the patient. The aim of the vaccine is to stimulate the immune system to mount an adaptive response to any remaining cancer cells with these mutations.[1][2][3]

Research

Pancreatic ductal adenocarcinoma

Phase I

Autogene cevumeran has completed a phase I trial in resectable pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer, which has provided preliminary evidence of good efficacy and safety.[3] The primary endpoint of the study was safety, while the secondary endpoints were 18-month overall survival (OS) and 18-month recurrence-free survival (RFS).

The study enrolled 34 patients, 28 of which underwent surgery to resect the PDAC. 19 of the patients who had undergone surgery then received atezolizumab, an immune checkpoint inhibitor. 16 of the patients on atezolizumab then received autogene cevumeran. 1 patient was considered to have insufficiently many neoantigens to manufacture the vaccine.

The patients who had received autogene cevumeran were classified as "responders" if IFNγ+ T cells against at least one of the neoantigens were detected by ELISpot (8 out of 16 patients in this study), and as "non-responders" otherwise (the remaining 8 patients). At the end of the study, the responders hadn't reached the 18-month RFS endpoint, meaning that their cancer hadn't recurred in the 18 months following treatment, while the non-responders had a median RFS of 13.4 months. The authors concluded that, given the preliminary evidence of efficacy and safety, an international phase 2 trial was imminent.

References

  1. ^ a b "BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication". BioNTech. 19 October 2023. Retrieved 1 January 2024.
  2. ^ a b "Genentech: Our Pipeline - Autogene cevumeran". Genentech. Retrieved 1 January 2024.
  3. ^ a b c Rojas, Luis A.; Sethna, Zachary; Soares, Kevin C.; Olcese, Cristina; Pang, Nan; Patterson, Erin; Lihm, Jayon; Ceglia, Nicholas; Guasp, Pablo; Chu, Alexander; Yu, Rebecca; Chandra, Adrienne Kaya; Waters, Theresa; Ruan, Jennifer; Amisaki, Masataka (May 2023). "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer". Nature. 618 (7963): 144–150. Bibcode:2023Natur.618..144R. doi:10.1038/s41586-023-06063-y. ISSN 1476-4687. PMC 10171177. PMID 37165196.


Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.